Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 500 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.
Follow-Up Questions
What is the price performance of PHMMF stock?
The current price of PHMMF is $93, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Pharma Mar SA?
Pharma Mar SA belongs to Biotechnology industry and the sector is Health Care
What is Pharma Mar SA market cap?
Pharma Mar SA's current market cap is $1.5B
Is Pharma Mar SA a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Pharma Mar SA, including 1 strong buy, 6 buy, 3 hold, 0 sell, and 1 strong sell
